Ketamine Infusions for RSD: What the Evidence Says
Reflex Sympathetic Dystrophy, commonly called RSD, is an older term for what clinicians now usually diagnose as complex regional pain syndrome type I, or CRPS-I. The condition can involve burning pain, unusual sensitivity to touch, swelling, temperature or color changes, stiffness, and reduced movement. CRPS type II involves a confirmed nerve injury and was formerly known as causalgia.
Ketamine has attracted attention because it affects NMDA receptors involved in pain signaling and central sensitization. Infusions are sometimes offered when standard treatments have not provided enough relief. However, the treatment remains specialized, and the available research is more limited than public interest may suggest.
People researching RSD health information should distinguish between promising findings, clinical experience, and established medical guidance. Ketamine may reduce pain for some patients, but it is not a guaranteed cure and does not reverse every physical or emotional effect of CRPS.
How Ketamine May Affect CRPS Pain
Ketamine is an NMDA receptor antagonist. By reducing certain signals associated with overactive pain processing, it may interrupt “wind-up,” a process in which the nervous system becomes increasingly responsive to painful or even harmless stimulation. This mechanism is relevant to CRPS, where pain can continue after the original injury has healed.
The medicine is usually given intravenously at a dose intended to treat pain rather than produce full anesthesia. Some pain specialists use a series of infusions over several days, while others use shorter outpatient sessions. Protocols vary considerably because there is no universally accepted dosing schedule for CRPS.
Ketamine may also produce temporary dissociation, sedation, dizziness, or changes in perception. These effects are part of the reason treatment requires medical supervision rather than unsupervised or at-home use.
What The Research Shows
Clinical trials and reviews suggest that intravenous ketamine can produce meaningful short-term pain reduction in some people with CRPS. A few controlled studies found better pain scores than placebo during or shortly after treatment, particularly among patients with longstanding, treatment-resistant disease. The duration of benefit has ranged from days to several weeks, with some observational studies reporting longer relief.
The evidence has important limitations. Studies are generally small, use different infusion schedules, and often measure pain more consistently than physical function, sleep, work capacity, or quality of life. Long-term safety and durability are also less certain. A response in one trial does not establish that every patient will benefit.
| Evidence Area | What Current Findings Suggest | Important Limitation |
|---|---|---|
| Short-term pain relief | Some patients experience substantial reduction during or after infusions | Response is inconsistent and may fade |
| Function and mobility | Improvement may occur when pain decreases enough to support rehabilitation | Functional gains are less consistently measured |
| Long-term control | A subset may report relief lasting weeks or longer | Strong evidence for durable benefit is lacking |
| Disease reversal | Ketamine has not been shown to reliably reverse CRPS | It is a symptom treatment, not a proven cure |
| Best treatment plan | Results may improve when paired with physical and psychological care | No single protocol is accepted everywhere |
Who May Be Considered
A specialist may consider ketamine when a person has a well-supported CRPS diagnosis, significant pain-related disability, and inadequate response to approaches such as physical therapy, desensitization, medications, nerve blocks, or psychological pain treatment. The decision should account for the duration of symptoms, prior treatments, sleep, mood, mobility, and the person’s goals.
Diagnosis still matters. CRPS is generally identified through a history, physical examination, and recognized clinical criteria such as the Budapest criteria. There is no single blood test or scan that confirms it. Other causes of neuropathic pain, infection, vascular disease, inflammatory disorders, and nerve injury may need to be excluded before an infusion is considered.
A pain physician may also assess cardiovascular health, liver function, current medicines, psychiatric history, and substance-use risk. Ketamine may be unsuitable or require special precautions for people with uncontrolled high blood pressure, serious cardiovascular disease, certain psychotic disorders, significant liver problems, or a history of adverse reactions.
What Treatment Usually Involves
Before treatment, the clinic should explain the expected benefit, alternatives, medication interactions, costs, and plan for follow-up. Baseline pain, movement, sleep, and daily activities can help determine whether the infusion produces a meaningful change rather than merely a brief alteration in perception.
During an infusion, clinicians commonly monitor blood pressure, heart rate, oxygen levels, alertness, and symptoms such as nausea or agitation. Patients may feel detached from their surroundings, see unusual images, or experience anxiety. A responsible program should have trained staff and emergency equipment available.
Afterward, patients generally need transportation and should avoid driving, alcohol, and important decisions until the medication has fully worn off. Physical therapy, graded movement, occupational therapy, and desensitization are often most useful when pain is controlled enough to permit active participation. Ketamine should support rehabilitation rather than replace it.
Risks, Side Effects, And Uncertainty
Short-term adverse effects can include nausea, vomiting, dizziness, drowsiness, increased blood pressure, rapid heart rate, blurred vision, and dissociation. Some people experience unpleasant hallucinations or panic-like reactions. These effects are more manageable when doses are carefully selected and monitoring is continuous.
Repeated or prolonged exposure raises additional concerns, including urinary or bladder problems, liver injury, tolerance, dependence, and misuse. The risk profile depends on dose, frequency, medical history, and whether ketamine is combined with sedatives, opioids, alcohol, or other medicines. Patients should disclose all prescriptions, supplements, and recreational substances.
A major practical concern is the gap between treatment marketing and evidence. Clinics may advertise dramatic or permanent results, yet research does not support a universal promise of lasting remission. Insurance coverage also varies, particularly because intravenous ketamine for chronic pain is generally an off-label use rather than an indication specifically approved by the U.S. Food and Drug Administration.
Building A Careful Treatment Plan
A considered decision should focus on measurable goals and a broader pain-management strategy. Useful questions include how long improvement is expected to last, what happens if the first infusion does not help, and how rehabilitation will be coordinated. A second opinion from a clinician experienced in CRPS can be valuable when the proposed protocol is unusually expensive or aggressive.
Before proceeding, discuss:
- The specific CRPS diagnosis and other possible explanations for symptoms
- The infusion dose, number of sessions, monitoring standards, and emergency procedures
- Likely benefits compared with physical therapy, medication changes, nerve stimulation, or psychological care
- Personal risks involving blood pressure, liver health, mood, substance use, and medication interactions
- The measures that will determine whether treatment is worth continuing
Living with persistent pain can also affect mood, relationships, sleep, and confidence in movement. Psychological support is not a suggestion that the pain is imaginary; it can help the nervous system, coping skills, and rehabilitation process work together.
Ketamine infusions may be a reasonable option for carefully selected people with severe, treatment-resistant CRPS, especially when used within a monitored program and paired with active rehabilitation. The evidence supports cautious optimism rather than certainty. Speak with a qualified pain specialist, review the risks and alternatives, and make sure any proposed treatment has clear goals and follow-up measures.